Introduction: The clinical effectiveness of AN69-oXiris remains unclear. This study aimed to compare the effects of AN69-oXiris and AN69-ST filters on cytokine levels and clinical improvement in septic patients. Methods: This prospective observational study recruited septic patients who underwent blood purification in the First Affiliated Hospital of Soochow University between December 2019 and May 2020. Patients were assigned to an AN69-oXiris (oXiris) or AN69-ST (ST) group based on their preferred filter. Patients’ clinical data, cytokine levels, and prognostic indicators were analysed at baseline (T0), 24 h after treatment (T1), and at the end of the treatment (T2). Results: Forty-four patients participated in this study (22 patients in each group). Participants in both groups showed improvements in mean arterial pressure (MAP) values, oxygenation indices, and urinary output, and decreased vasoactive-inotropic scores (VISs), heart rates, lactic acid levels, and serum creatinine levels after blood purification. Reductions in cytokine levels were observed at T1 in both groups. Improvement the haemodynamic status was higher in the oXiris group than in the ST group at T2 (MAP: 79.0 [76.0, 85.0] vs. 77.0 [72.75, 79.25] mm Hg, p = 0.04; VISs: 9.10 [0.00, 16.69] vs. 19.05 [10.60, 26.33], p = 0.03, respectively). Patients in the oXiris group also had lower cytokine levels than those in the ST group at T1 (tumour necrosis factor-α: 24.55 [16.9, 30.15] vs. 30.15 [23.38, 34.13] pg/mL, p = 0.04; interleukin (IL)-6: 66.63 [46.21, 102.20] vs. 125.48 [79.73, 167.97] pg/mL, p = 0.01; IL-8: 53.59 [35.10, 66.01] vs. 63.60 [45.58, 83.37] pg/mL, p = 0.04; IL-10: 13.50 [10.35, 18.68] vs. 17.15 [13.80, 21.95] pg/mL, p = 0.04, respectively). There were no significant differences between the 2 groups regarding hospital mortality, intensive care unit length of stay (LOS), and hospital LOS. Conclusion: Blood purification using the AN69-oXiris or AN69-ST filter proved useful for septic patients, which was associated with reduced cytokine levels and improved clinical condition. Patients treated with AN69-oXiris had a more remarkable improvement in haemodynamic status and lower cytokine levels than those treated with AN69-ST filter, but there were no differences in clinical outcomes. Further investigations are needed to prove this finding.

1.
Fleischmann
C
,
Scherag
A
,
Adhikari
NK
,
Hartog
CS
,
Tsaganos
T
,
Schlattmann
P
,
Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations
.
Am J Respir Crit Care Med
.
2016
;
193
(
3
):
259
72
. .
2.
Fujishima
S
.
Organ dysfunction as a new standard for defining sepsis
.
Inflamm Regen
.
2016
;
36
:
24
. .
3.
Hartman
ME
,
Linde-Zwirble
WT
,
Angus
DC
,
Watson
RS
.
Trends in the epidemiology of pediatric severe sepsis
.
Pediatr Crit Care Med
.
2013
;
14
(
7
):
686
93
. .
4.
Rhodes
A
,
Evans
LE
,
Alhazzani
W
,
Levy
MM
,
Antonelli
M
,
Ferrer
R
,
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016
.
Intensive Care Med
.
2017
;
43
(
3
):
304
77
. .
5.
Rello
J
,
Valenzuela-Sánchez
F
,
Ruiz-Rodriguez
M
,
Moyano
S
.
Sepsis: a review of advances in management
.
Adv Ther
.
2017
;
34
(
11
):
2393
411
. .
6.
Girardot
T
,
Schneider
A
,
Rimmelé
T
.
Blood purification techniques for sepsis and septic AKI
.
Semin Nephrol
.
2019
;
39
(
5
):
505
14
. .
7.
Monard
C
,
Rimmelé
T
,
Ronco
C
.
Extracorporeal blood purification therapies for sepsis
.
Blood Purif
.
2019
;
47
(
Suppl 3
):
1
14
. .
8.
Payen
DM
,
Guilhot
J
,
Launey
Y
,
Lukaszewicz
AC
,
Kaaki
M
,
Veber
B
,
Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial
.
Intensive Care Med
.
2015
;
41
(
6
):
975
84
. .
9.
Srisawat
N
,
Tungsanga
S
,
Lumlertgul
N
,
Komaenthammasophon
C
,
Peerapornratana
S
,
Thamrongsat
N
,
The effect of polymyxin B hemoperfusion on modulation of human leukocyte antigen DR in severe sepsis patients
.
Crit Care
.
2018
;
22
(
1
):
279
. .
10.
Broman
ME
,
Hansson
F
,
Vincent
JL
,
Bodelsson
M
.
Endotoxin and cytokine reducing properties of the oXiris membrane in patients with septic shock: a randomized crossover double-blind study
.
PLoS One
.
2019
;
14
(
8
):
e0220444
. .
11.
Malard
B
,
Lambert
C
,
Kellum
JA
.
In vitro comparison of the adsorption of inflammatory mediators by blood purification devices
.
Intensive Care Med Exp
.
2018
;
6
(
1
):
12
. .
12.
Singer
M
,
Deutschman
CS
,
Seymour
CW
,
Shankar-Hari
M
,
Annane
D
,
Bauer
M
,
The third international consensus definitions for sepsis and septic shock (sepsis-3)
.
JAMA
.
2016
;
315
(
8
):
801
10
. .
13.
Khwaja
A
.
KDIGO clinical practice guidelines for acute kidney injury
.
Nephron Clin Pract
.
2012
;
120
(
4
):
c179
84
. .
14.
Frohlich
M
,
Wafaisade
A
,
Mansuri
A
,
Koenen
P
,
Probst
C
,
Maegele
M
,
Which score should be used for posttraumatic multiple organ failure? Comparison of the MODS, Denver- and SOFA- Scores
.
Scand J Trauma Resusc Emerg Med
.
2016
;
24
(
1
):
130
.
15.
Levy
MM
,
Evans
LE
,
Rhodes
A
.
The surviving sepsis campaign bundle: 2018 update
.
Crit Care Med
.
2018
;
46
(
6
):
997
1000
. .
16.
Schilder
L
,
Nurmohamed
SA
,
Bosch
FH
,
Purmer
IM
,
den Boer
SS
,
Kleppe
CG
,
Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial
.
Crit Care
.
2014
;
18
(
4
):
472
. .
17.
Kumar
M
,
Sharma
R
,
Sethi
SK
,
Bazaz
S
,
Sharma
P
,
Bhan
A
,
Vasoactive inotrope score as a tool for clinical care in children post cardiac surgery
.
Indian J Crit Care Med
.
2014
;
18
(
10
):
653
8
. .
18.
Garcia
RU
,
Walters
HL
 3rd
,
Delius
RE
,
Aggarwal
S
.
Vasoactive Inotropic Score (VIS) as Biomarker of short-term outcomes in adolescents after cardiothoracic surgery
.
Pediatr Cardiol
.
2016
;
37
(
2
):
271
7
. .
19.
Budniok
T
,
ElSayed
Y
,
Louis
D
.
Effect of vasopressin on systemic and pulmonary hemodynamics in neonates
.
Am J Perinatol
.
2020
. .
20.
Turani
F
,
Barchetta
R
,
Falco
M
,
Busatti
S
,
Weltert
L
.
Continuous renal replacement therapy with the adsorbing filter oXiris in septic patients: a case series
.
Blood Purif
.
2019
;
47
(
Suppl 3
):
1
5
. .
21.
Cohen
J
.
A power primer
.
Psychol Bull
.
1992
;
112
(
1
):
155
9
. .
22.
Beutler
B
.
Endotoxin, toll-like receptor 4, and the afferent limb of innate immunity
.
Curr Opin Microbiol
.
2000
;
3
(
1
):
23
8
. .
23.
Grin
PM
,
Dwivedi
DJ
,
Chathely
KM
,
Trigatti
BL
,
Prat
A
,
Seidah
NG
,
Low-density lipoprotein (LDL)-dependent uptake of Gram-positive lipoteichoic acid and Gram-negative lipopolysaccharide occurs through LDL receptor
.
Sci Rep
.
2018
;
8
(
1
):
10496
. .
24.
Gomez
H
,
Ince
C
,
De Backer
D
,
Pickkers
P
,
Payen
D
,
Hotchkiss
J
,
A unified theory of sepsis-induced acute kidney injury: inflammation, microcirculatory dysfunction, bioenergetics, and the tubular cell adaptation to injury
.
Shock
.
2014
;
41
(
1
):
3
11
. .
25.
Tamayo
E
,
Fernández
A
,
Almansa
R
,
Carrasco
E
,
Heredia
M
,
Lajo
C
,
Pro- and anti-inflammatory responses are regulated simultaneously from the first moments of septic shock
.
Eur Cytokine Netw
.
2011
;
22
(
2
):
82
7
. .
26.
Gogos
CA
,
Drosou
E
,
Bassaris
HP
,
Skoutelis
A
.
Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options
.
J Infect Dis
.
2000
;
181
(
1
):
176
80
. .
27.
Henry
BM
,
Benoit
SW
,
Vikse
J
,
Berger
BA
,
Pulvino
C
,
Hoehn
J
,
The anti-inflammatory cytokine response characterized by elevated interleukin-10 is a stronger predictor of severe disease and poor outcomes than the pro-inflammatory cytokine response in coronavirus disease 2019 (COVID-19)
.
Clin Chem Lab Med
.
2021
;
59
(
3
):
599
607
. .
28.
Brandenburger
T
,
Dimski
T
,
Slowinski
T
,
Kindgen-Milles
D
.
Renal replacement therapy and anticoagulation
.
Best Pract Res Clin Anaesthesiol
.
2017
;
31
(
3
):
387
401
. .
29.
Chanard
J
,
Lavaud
S
,
Maheut
H
,
Kazes
I
,
Vitry
F
,
Rieu
P
.
The clinical evaluation of low-dose heparin in haemodialysis: a prospective study using the heparin-coated AN69 ST membrane
.
Nephrol Dial Transplant
.
2008
;
23
(
6
):
2003
9
. .
30.
Lumlertgul
N
,
Srisawat
N
.
The haemodynamic effects of oXiris haemofilter in septic shock patients requiring renal support: a single-centre experience
.
Int J Artif Organs
.
2020
:
391398820917150
. .
31.
Shum
HP
,
Chan
KC
,
Kwan
MC
,
Yan
WW
.
Application of endotoxin and cytokine adsorption haemofilter in septic acute kidney injury due to Gram-negative bacterial infection
.
Hong Kong Med J
.
2013
;
19
(
6
):
491
7
. .
32.
Schwindenhammer
V
,
Girardot
T
,
Chaulier
K
,
Gregoire
A
,
Monard
C
,
Huriaux
L
,
oXiris(R) use in septic shock: experience of two french centres
.
Blood Purif
.
2019
;
47
(
Suppl 3
):
1
7
.
33.
Castellheim
A
,
Brekke
OL
,
Espevik
T
,
Harboe
M
,
Mollnes
TE
.
Innate immune responses to danger signals in systemic inflammatory response syndrome and sepsis
.
Scand J Immunol
.
2009
;
69
(
6
):
479
91
. .
34.
Vaishnavi
C
.
Translocation of gut flora and its role in sepsis
.
Indian J Med Microbiol
.
2013
;
31
(
4
):
334
. .
35.
Hayashi
K
,
Sasabuchi
Y
,
Matsui
H
,
Nakajima
M
,
Ohbe
H
,
Fushimi
K
,
In-hospital mortality after blood purification with and without acrylonitrile-co-methallyl sulfonate surface-treated membrane for pneumoniaassociated sepsis: a retrospective cohort study
.
Research Square
.
2020
.
36.
Hayashi
K
,
Sasabuchi
Y
,
Matsui
H
,
Nakajima
M
,
Ohbe
H
,
Ono
K
,
Clinical effect of the acrylonitrile-co-methallyl sulfonate surface-treated membrane as a cytokine adsorption therapy for sepsis due to acute panperitonitis: a retrospective cohort study
.
Blood Purif
.
2020
;
49
(
3
):
364
71
. .
37.
Tanaka
A
,
Inaguma
D
,
Nakamura
T
,
Watanabe
Y
,
Ito
E
,
Kamegai
N
,
Effect of continuous hemodiafiltration using an AN69ST membrane in patients with sepsis
.
Renal Replacement Therapy
.
2017
;
3
(
1
).
38.
Shiga
H
,
Hirasawa
H
,
Nishida
O
,
Oda
S
,
Nakamura
M
,
Mashiko
K
,
Continuous hemodiafiltration with a cytokine-adsorbing hemofilter in patients with septic shock: a preliminary report
.
Blood Purif
.
2014
;
38
(
3–4
):
211
8
. .
39.
Guven
H
,
Altintop
L
,
Baydin
A
,
Esen
S
,
Aygun
D
,
Hokelek
M
,
Diagnostic value of procalcitonin levels as an early indicator of sepsis
.
Am J Emerg Med
.
2002
;
20
(
3
):
202
6
. .
40.
Szederjesi
J
,
Almasy
E
,
Lazar
A
,
Huțanu
A
,
Badea
I
,
Georgescu
A
.
An evaluation of serum procalcitonin and c-reactive protein levels as diagnostic and prognostic biomarkers of severe sepsis
.
J Crit Care Med
.
2015
;
1
(
4
):
147
53
. .
41.
Enguix-Armada
A
,
Escobar-Conesa
R
,
García-De La Torre
A
,
De La Torre-Prados
MV
.
Usefulness of several biomarkers in the management of septic patients: C-reactive protein, procalcitonin, presepsin and mid-regional pro-adrenomedullin
.
Clin Chem Lab Med
.
2016
;
54
(
1
):
163
8
. .
42.
Dahaba
AA
,
Elawady
GA
,
Rehak
PH
,
List
WF
.
Procalcitonin and proinflammatory cytokine clearance during continuous venovenous haemofiltration in septic patients
.
Anaesth Intensive Care
.
2002
;
30
(
3
):
269
74
. .
43.
Honore
PM
,
Jacobs
R
,
De Waele
E
,
Van Gorp
V
,
Spapen
HD
.
Biomarkers of inflammation during continuous renal replacement therapy: sensors, players, or targets? A reply to the letter by villa et al
.
Blood Purification
.
2014
;
38
(
2
):
102
.
44.
Slaats
J
,
Ten Oever
J
,
van de Veerdonk
FL
,
Netea
MG
.
IL-1beta/IL-6/CRP and IL-18/ferritin: distinct inflammatory programs in infections
.
PLoS Pathog
.
2016
;
12
(
12
):
e1005973
.
45.
Davies
J
.
Procalcitonin
.
J Clin Pathol
.
2015
;
68
(
9
):
675
9
. .
46.
Baranowsky
A
,
Appelt
J
,
Kleber
C
,
Lange
T
,
Ludewig
P
,
Jahn
D
,
Procalcitonin exerts a mediator role in septic shock through the calcitonin gene-related peptide receptor
.
Crit Care Med
.
2021
;
49
(
1
):
e41
52
. .
47.
Schuetz
P
,
Birkhahn
R
,
Sherwin
R
,
Jones
AE
,
Singer
A
,
Kline
JA
,
Serial procalcitonin predicts mortality in severe sepsis patients: results from the multicenter procalcitonin monitoring sepsis (MOSES) study
.
Crit Care Med
.
2017
;
45
(
5
):
781
9
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.